AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment f
AstraZeneca and Eli Lilly and Company (Lilly) have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial.
Click on this link for more information.
